FDA reviews Boehringer's Spiriva HandiHaler for stroke risk

The FDA announced Tuesday that it is conducting a safety review of Boehringer Ingelheim's Spiriva HandiHaler, a treatment for chronic obstructive pulmonary disease, after the company reported that it may increase the risk of stroke. The agency has asked the company to submit more data on the inhaler but warned patients against discontinuing treatment without proper medical advice.

View Full Article in:

Washington Post, The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA